Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

A Comprehensive Diverse '-omics' Approach to Better Understanding the Molecular Pathomechanisms of Down Syndrome.

Ishihara K, Akiba S.

Brain Sci. 2017 Apr 21;7(4). pii: E44. doi: 10.3390/brainsci7040044. Review.

2.

Ts1Cje Down syndrome model mice exhibit environmental stimuli-triggered locomotor hyperactivity and sociability concurrent with increased flux through central dopamine and serotonin metabolism.

Shimohata A, Ishihara K, Hattori S, Miyamoto H, Morishita H, Ornthanalai G, Raveau M, Ebrahim AS, Amano K, Yamada K, Sago H, Akiba S, Mataga N, Murphy NP, Miyakawa T, Yamakawa K.

Exp Neurol. 2017 Mar 20;293:1-12. doi: 10.1016/j.expneurol.2017.03.009. [Epub ahead of print]

PMID:
28336394
3.

Normal model construction for statistical image analysis of torso FDG-PET images based on anatomical standardization by CT images from FDG-PET/CT devices.

Takeda K, Hara T, Zhou X, Katafuchi T, Kato M, Ito S, Ishihara K, Kumita S, Fujita H.

Int J Comput Assist Radiol Surg. 2017 Feb 6. doi: 10.1007/s11548-017-1526-4. [Epub ahead of print]

PMID:
28168681
4.

Brain ventriculomegaly in Down syndrome mice is caused by Pcp4 dose-dependent cilia dysfunction.

Raveau M, Nakahari T, Asada S, Ishihara K, Amano K, Shimohata A, Sago H, Yamakawa K.

Hum Mol Genet. 2017 Mar 1;26(5):923-931. doi: 10.1093/hmg/ddx007.

PMID:
28069794
5.

The high matrix acquisition technique for imaging of atherosclerotic plaque inflammation in fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with time-of-flight: Phantom study.

Suda M, Kiriyama T, Ishihara K, Onoguchi M, Kobayashi Y, Sakurai M, Shibutani T, Kumita SI.

J Nucl Cardiol. 2016 May 19. [Epub ahead of print]

PMID:
27197819
6.

Group IVA phospholipase A(2) deficiency prevents CCl4-induced hepatic cell death through the enhancement of autophagy.

Ishihara K, Kanai S, Tanaka K, Kawashita E, Akiba S.

Biochem Biophys Res Commun. 2016 Feb 26;471(1):15-20. doi: 10.1016/j.bbrc.2016.01.186. Epub 2016 Feb 3.

PMID:
26850849
7.

ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease.

Kanai S, Ishihara K, Kawashita E, Tomoo T, Nagahira K, Hayashi Y, Akiba S.

J Pharmacol Exp Ther. 2016 Mar;356(3):604-14. doi: 10.1124/jpet.115.229906. Epub 2015 Dec 23.

8.

Patients with reduced heart rate response to adenosine infusion have low myocardial flow reserve in (13)N-ammonia PET studies.

Tomiyama T, Kumita S, Ishihara K, Suda M, Sakurai M, Hakozaki K, Hashimoto H, Takahashi N, Takano H, Kobayashi Y, Kiriyama T, Fukushima Y, Shimizu W.

Int J Cardiovasc Imaging. 2015 Jun;31(5):1089-95. doi: 10.1007/s10554-015-0654-6. Epub 2015 Apr 7.

9.

Production of interleukin (IL)-33 in the lungs during multiple antigen challenge-induced airway inflammation in mice, and its modulation by a glucocorticoid.

Nabe T, Wakamori H, Yano C, Nishiguchi A, Yuasa R, Kido H, Tomiyama Y, Tomoda A, Kida H, Takiguchi A, Matsuda M, Ishihara K, Akiba S, Ohya S, Fukui H, Mizutani N, Yoshino S.

Eur J Pharmacol. 2015 Jun 15;757:34-41. doi: 10.1016/j.ejphar.2015.03.015. Epub 2015 Mar 20.

PMID:
25797285
10.

The reproducibility of time-of-flight PET and conventional PET for the quantification of myocardial blood flow and coronary flow reserve with (13)N-ammonia.

Suda M, Onoguchi M, Tomiyama T, Ishihara K, Takahashi N, Sakurai M, Matsumoto K, Kumita S.

J Nucl Cardiol. 2016 Jun;23(3):457-72. doi: 10.1007/s12350-015-0074-y. Epub 2015 Mar 17.

PMID:
25777781
11.

Impact of time-of-flight on qualitative and quantitative analyses of myocardial perfusion PET studies using (13)N-ammonia.

Tomiyama T, Ishihara K, Suda M, Kanaya K, Sakurai M, Takahashi N, Takano H, Nitta K, Hakozaki K, Kumita S.

J Nucl Cardiol. 2015 Oct;22(5):998-1007. doi: 10.1007/s12350-014-0037-8. Epub 2014 Dec 3.

12.

Amyloid imaging with [(18)F]florbetapir in geriatric depression: early-onset versus late-onset.

Tateno A, Sakayori T, Higuchi M, Suhara T, Ishihara K, Kumita S, Suzuki H, Okubo Y.

Int J Geriatr Psychiatry. 2015 Jul;30(7):720-8. doi: 10.1002/gps.4215. Epub 2014 Oct 21.

PMID:
25335941
13.

Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.

Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, Mintun MA, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y.

Int J Geriatr Psychiatry. 2015 May;30(5):505-13. doi: 10.1002/gps.4173. Epub 2014 Jul 7.

PMID:
25043833
14.

Gastric emptying of a carbohydrate-electrolyte solution in healthy volunteers depends on osmotically active particles.

Kim C, Okabe T, Sakurai M, Kanaya K, Ishihara K, Inoue T, Kumita S, Sakamoto A.

J Nippon Med Sch. 2013;80(5):342-9.

15.
16.

Significant suppression of myocardial (18)F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet.

Kobayashi Y, Kumita S, Fukushima Y, Ishihara K, Suda M, Sakurai M.

J Cardiol. 2013 Nov;62(5):314-9. doi: 10.1016/j.jjcc.2013.05.004. Epub 2013 Jun 26.

17.

Underestimation of the ejection fraction using the quantitative gated SPECT for patients with myocardial hypertrophy.

Yamaguchi H, Toba M, Amano Y, Ishihara K, Mizuno K, Kumita S.

Ann Nucl Med. 2013 Jul;27(6):502-7. doi: 10.1007/s12149-013-0713-9. Epub 2013 Mar 15.

PMID:
23494211
18.

Effect of a peroxynitrite scavenger, a manganese-porphyrin compound on airway remodeling in a murine asthma.

Cao Y, Fujii M, Ishihara K, Akiba S, Yasui H, Nabe T.

Biol Pharm Bull. 2013;36(5):850-5. Epub 2013 Feb 25.

19.

Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.

Tateno A, Arakawa R, Okumura M, Fukuta H, Honjo K, Ishihara K, Nakamura H, Kumita S, Okubo Y.

J Clin Psychopharmacol. 2013 Apr;33(2):162-9. doi: 10.1097/JCP.0b013e3182825bce.

PMID:
23422369
20.

Group IVA phospholipase A2 participates in the progression of hepatic fibrosis.

Ishihara K, Miyazaki A, Nabe T, Fushimi H, Iriyama N, Kanai S, Sato T, Uozumi N, Shimizu T, Akiba S.

FASEB J. 2012 Oct;26(10):4111-21. doi: 10.1096/fj.12-205625. Epub 2012 Jun 29.

PMID:
22750514

Supplemental Content

Loading ...
Support Center